placebo subcutaneous administration

DRUG2 trials

Sponsors

Laekna Limited, Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

Conditions

IgA Nephropathy (IgAN)Overweight and Obese Volunteers

Phase 1

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

RecruitingNCT06493084

Laekna LimitedOverweight and Obese Volunteers

Start: 2024-06-25End: 2026-09-30Target: 160Updated: 2026-01-09

Phase 2

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

RecruitingNCT07305974

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.IgA Nephropathy (IgAN)

Start: 2025-09-08End: 2029-03-31Target: 30Updated: 2025-12-26